Portal de Periódicos da CAPES

ERCC1 mRNA levels and survival of advanced gastric cancer patients treated with a modified FOLFOX regimen

2008; Springer Nature; Volume: 98; Issue: 8 Linguagem: Inglês

10.1038/sj.bjc.6604317

1532-1827

Jia Wei, Zhengyun Zou, Xiaoping Qian, Yitao Ding, Li Xie, José Javier Sánchez, Yang Zhao, J. Feng, Ling Ye, Yvxuan Liu, Lixia Yu, Rafael Rosell, B Liu,

Gastric Cancer Management and Outcomes

Molecular markers involved in DNA repair can help to predict survival in gastric cancer patients treated with 5-FU plus platinum chemotherapy. Excision repair cross-complementing 1 (ERCC1) and thymidylate synthase (TS) mRNA expression levels were assessed in advanced gastric cancer tumour samples using real-time quantitative PCR in 76 patients treated with a modified FOLFOX (biweekly oxaliplatin plus 5-FU and folinic acid) regimen. Median survival time in patients with low ERCC1 levels was significantly longer than in those with high levels (15.8 vs 6.2 months; P<0.0001). Patients with high TS levels had longer survival than those with low levels (12.2 vs 10.1 months; P=0.01). Forty-eight patients with low ERCC1 and high TS levels had a median survival of 16.1 months (P<0.0001). The hazard ratio for patients with high ERCC1 expression was 9.4 (P<0.0001). In patients with high mRNA levels of ERCC1, alternative chemotherapy regimens should be considered.